Companies
Bolt
- Country
- United States
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ | ✓ |
| specialty-fine-chem | ✓ | ✓ | — | ✓ |
Regulatorsfdaechanmpaemaepareachusda-aphis
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | The company relies on external capital and collaborations; as of June 30, 2026, it held $18.1 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the first quarter of 2027. | sec.gov · stocktitan.net |
| Capacity | The company does not own or operate any manufacturing facilities and relies on third-party contract development and manufacturing organizations (CDMOs). | sec.gov |
| Regulatory approval | The company's product candidates, such as BDC-4182, require FDA approval via a Biologics License Application (BLA) before they can be marketed in the United States. | sec.gov |
| Production site | The company does not own manufacturing facilities and relies on third-party CDMOs; its corporate office and laboratory space is in Redwood City, California. | sec.gov |
| Headcount | A major October 2025 restructuring cut headcount by approximately 50%. | stocktitan.net |
| Revenue | Total collaboration revenue was $5,000 for the second quarter of 2026 and $18,000 for the six months ended June 30, 2026. | boltbiotherapeutics.gcs-web.com · sec.gov · stocktitan.net |
Independent sources: sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio-camouflage & bio-armor materials | fibers-textiles | Medium | → |
| Biotech in the textile industry | fibers-textiles | Medium | → |
| Natural fibers & bio-textiles | fibers-textiles | Medium | → |
| Recombinant spider silk & engineered protein fibers | fibers-textiles | Medium | → |
| Silk fibroin (recombinant, biomaterials) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.